github link
Accession IconGSE7035

Synergy between PPARgamma ligands and platinum-based drugs in cancer

Organism Icon Homo sapiens
Sample Icon 7 Downloadable Samples
Technology Badge Icon Affymetrix Human Genome U133A Array (hgu133a)

Submitter Supplied Information

PPAR is a member of the nuclear receptor family for which agonist ligands have anti-growth effects. However, clinical studies using PPAR ligands as a monotherapy failed to show a beneficial effect. Here we have studied the effects of PPAR activation with chemotherapeutic agents in current use for specific cancers. We observed a striking synergy between rosiglitazone and platinum-based drugs in several different cancers both in vitro and using transplantable and chemically induced spontaneous tumor models. The effect appears to be due in part to PPAR-mediated downregulation of metallothioneins, proteins that have been shown to be involved in resistance to platinum-based therapy. These data strongly suggest combining PPAR agonists and platinum-based drugs for the treatment of certain human cancers
PubMed ID
Total Samples
Submitter’s Institution
Alternate Accession IDs


Show of 0 Total Samples
Accession Code
Processing Information
Additional Metadata
No rows found